Genentech, Inc.
NEWS
Earlier this week Amneal Pharmaceuticals and Impax Laboratories completed their business merger, forming the new Amneal Pharmaceuticals. The combined companies are now the fifth largest generics business in the United States.
Lodo Therapeutics, based in New York, formed a strategic drug discovery collaboration with Genentech, a Roche company, in a deal potentially worth more than $1 billion.
As we get closer to seeing the U.S. Food and Drug Administration green light the first gene therapy for hemophilia, analysts estimate that the cost of the probable one-time treatment could have a whopping price-tag of $1.5 million.
The U.S. Food and Drug Administration (FDA) granted Genentech’s Tecentriq triple combination with Avastain (bevacizumab), paclitaxel and carboplatin (chemotherapy) Priority Review for first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC).
According to Biosimilarpipeline, more than 660 companies worldwide have about 700 biosimilars in development.
The U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) to Sandoz, a division of Novartis, for its Biologics Licensing Application (BLA) for its biosimilar to Roche/Genentech’s Rituxan.
Casma Therapeutics closed on a Series A round totaling $58.5 million. The company was solely funded by Third Rock Ventures.
Eli Lilly and Company announced that Leena Gandhi will lead its immuno-oncology medical development program.
Despite strong sales of shingles vaccine Shingrix, GlaxoSmithKline reported its sales and earnings fell 2 percent in the first quarter of the year, largely due to challenges in respiratory sales as well as significant currency impact.
JOBS
IN THE PRESS